



*POST-SABCS* Issue 1, 2013

**A Phase II Study of Letrozole  
with or without PD 0332991  
as First-Line Therapy for  
Advanced Breast Cancer**

For more visit [ResearchToPractice.com/5MJCSABCS2013](http://ResearchToPractice.com/5MJCSABCS2013)

Research  
To Practice®

## CME INFORMATION

### OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. This unique conference provides many clinicians and scientists from around the world a forum for discussing critical issues in the prevention and management of breast cancer. Therefore, SABCS is targeted by many members of the clinical research community as the optimal time to unveil new clinical data. This creates an environment in which yearly published results from a plethora of ongoing clinical trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes.

Although SABCS currently offers online access to the vast majority of the poster and plenary presentations from the annual meeting, the absence of expert assessment concerning practical applications may yield confusion among community oncologists who are challenged almost daily to appropriately apply a multitude of scientific findings across diverse tumors. Thus, identification of those data sets with immediate or impending relevance to the delivery of quality breast cancer care, in conjunction with professional commentary to address resultant practice ambiguity, may prove vastly beneficial to those physicians who are unable to make the annual pilgrimage to San Antonio. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS, including expert perspectives on how these new evidence-based concepts can and should be incorporated into on- and off-protocol patient care. This activity will assist medical oncologists, radiation oncologists, breast/general surgeons, nurses and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

### LEARNING OBJECTIVES

- Apply the results of emerging research evaluating the optimal dose of fulvestrant to the clinical care of postmenopausal patients with locally advanced or metastatic breast cancer.
- Evaluate the contributory effects of bevacizumab when added to standard endocrine therapy for postmenopausal patients with unresectable, locally advanced or metastatic breast cancer.
- Integrate new clinical trial data supporting the extended use of adjuvant tamoxifen beyond 5 years to the treatment of patients with localized estrogen receptor-positive breast cancer.
- Describe the rationale for and emerging efficacy and tolerability data with the novel combination of endocrine therapy and a cyclin-dependent kinase 4/6 inhibitor for postmenopausal women with hormone receptor-positive advanced breast cancer.

### ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at [ResearchToPractice.com/5MJCSABCS2013/1/CME](http://ResearchToPractice.com/5MJCSABCS2013/1/CME).

### CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Lisa A Carey, MD  
Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research  
Chief, Division of Hematology and Oncology  
Physician-in-Chief  
North Carolina Cancer Hospital  
Associate Director for Clinical Research  
Lineberger Comprehensive Cancer Center  
Chapel Hill, North Carolina

Advisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Research Support: Genentech BioOncology, GlaxoSmithKline, Sanofi.

Rowan T Chlebowski, MD, PhD  
Professor of Medicine  
David Geffen School of Medicine at UCLA  
Chief, Division of Medical Oncology and Hematology  
Harbor-UCLA Medical Center  
Torrance, California

Advisory Committee: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation; Consulting Agreement: Pfizer Inc; Speakers Bureau: Novartis Pharmaceuticals Corporation.

Clifford Hudis, MD  
Chief, Breast Cancer Medicine Service  
Solid Tumor Division  
Department of Medicine  
Memorial Sloan-Kettering Cancer Center  
Professor of Medicine  
Weill Cornell Medical College  
New York, New York

No real or apparent conflicts of interest to disclose.

Edith A Perez, MD  
Deputy Director at Large, Mayo Clinic Cancer Center  
Group Vice Chair, Alliance of Clinical Trials in Oncology  
Serene M and Frances C Durling Professor of Medicine  
Mayo Clinic  
Jacksonville, Florida

Contracted Research: Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline.

Sir Richard Peto  
Professor of Medical Statistics  
Co-director, Clinical Trial Service Unit  
University of Oxford  
Oxford, United Kingdom

No real or apparent conflicts of interest to disclose. Prof Peto was not paid for his interview.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Eisai Inc, Genentech BioOncology and Genomic Health Inc.

Hardware/Software Requirements:

A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more  
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later  
Adobe Flash Player 10.2 plug-in or later  
Adobe Acrobat Reader  
(Optional) Sound card and speakers for audio

Last review date: February 2013

Expiration date: February 2014

## SABCS highlights: Should adjuvant tamoxifen now be administered for 10 years?

To go directly to slides and commentary for this issue, [click here](#).

In 1995 the National Cancer Institute (NCI) mailed a “Clinical Alert” to oncologists strongly cautioning them to limit the duration of adjuvant tamoxifen (TAM) to 5 years based on data from NSABP and Scottish trials demonstrating no advantage and perhaps a detriment with prolonged endocrine treatment. While investigators worldwide endorsed this recommendation, legendary Oxford statistician Sir Richard Peto and his cadre were not convinced and regularly noted (most memorably in a fiery exchange during the 2000 NIH/NCI Breast Cancer Consensus Conference) that the available data on TAM duration were inadequately powered to answer the question. Further, they believed there was a substantial likelihood that longer treatment would yield greater benefit and to that end championed the launch of 2 massive international trials — ATLAS and **aTTom** — comparing 5 years to 10 years of TAM.

More than a decade later, this past December during the San Antonio Breast Cancer Symposium, Peto (as usual) had the last word when his colleague Richard Gray presented the dramatic findings from the ATLAS trial demonstrating a clear-cut and meaningful advantage in favor of continuing TAM for 10 years. As ATLAS was quite likely the biggest story coming out of the meeting by the river, we decided to kick off this year’s post-SABCS series by profiling that and other endocrine-related papers:

### 1. [ATLAS \(10 versus 5 years of adjuvant TAM\)](#)

Perhaps the most fascinating aspect of this historic study is how ER-positive disease evolves over time and the impressive carryover effect of endocrine treatment that persists for up to a decade after discontinuation. Several weeks after San Antonio, in another in a series of audio interviews I’ve done with Dr Peto stretching back more than 20 years, he emphasized the profound delayed impact of adjuvant hormonal therapy and pointed out that the full measure of benefit of 10 years of TAM won’t be determined until about 2018.

Although more follow-up is welcome, it also seems that there is now a rapidly developing consensus based on the ATLAS findings that treatment should be continued

out to 10 years in patients who remain premenopausal after 5 years of TAM. Treatment for patients who become menopausal during the first 5 years of TAM is far less clear cut, but switching to an aromatase inhibitor and continuing therapy is another logical option. For postmenopausal women with an intact uterus, the risk-benefit profile of 10 years of TAM is controversial.

## **2. Encouraging data with letrozole in combination with a cyclin-dependent kinase (CDK) inhibitor**

CDKs play a critical role in regulating cell-cycle progression, and laboratory evidence suggests possible synergy between CDK inhibition and endocrine treatment. Those observations led to a randomized Phase II trial in postmenopausal women comparing the CDK inhibitor PD 0332991 combined with letrozole to letrozole alone, which at San Antonio demonstrated an improvement in progression-free survival (PFS) from 7.5 to 26.1 months in favor of the combination, with minimal additional toxicity, mainly myelosuppression. Although there was considerable excitement surrounding these impressive results, all agree that a Phase III trial will determine if this is for real or just iniparib-esque hype that will lead to disappointment.

## **3. Survival benefit of 500 mg vs 250 mg fulvestrant**

With an overall survival (OS) hazard rate of 0.81, this is one of the few Phase III breast cancer trials of any type that shows that dose really can matter. The study supports the current widely used practice of administering 500-mg fulvestrant, and one wonders if this fascinating agent will ever be studied in an adjuvant trial.

## **4. Bevacizumab (bev) and endocrine treatment for metastatic disease (LEA trial)**

Same old story here as this Phase III study demonstrated a modest trend for PFS benefit in favor of bev without any effect on survival. This leads to a logical question: Is this the end of the line for anti-angiogenic agents in breast cancer until the ECOG adjuvant bev trial results mature? The answer is not as simple as you might think given the **surprising positive trial results recently reported in metastatic gastric cancer** showing a PFS and OS advantage for monotherapy with a monoclonal antibody to the VEGF receptor 2 (ramucirumab) suggesting that we may not have seen the end of positive research findings with this strategy.

## **5. SWOG-S1207: Adjuvant everolimus with endocrine treatment**

This important study, highlighted during the conference's ongoing clinical trials session, supports the notion that "the best clinical option is often trial participation." Many patients with ER-positive, HER2-negative tumors have less than optimal long-term outcomes with endocrine treatment and chemotherapy, and this study allows patients

the opportunity to maybe fare better by adding an agent with encouraging supportive data in the metastatic setting.

Next in this series: Metastatic HER2-positive disease — where the world awaits the much-needed approval of the antibody-drug conjugate trastuzumab emtansine (T-DM1), and we review more data from San Antonio on the other major recent addition to the field, the HER2 dimerization inhibitor pertuzumab.

Neil Love, MD

**Research To Practice**

Miami, Florida

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice designates this enduring material for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by educational grants from Eisai Inc, Genentech BioOncology and Genomic Health Inc.

# **A Phase II Study of Letrozole with or without PD 0332991 as First-Line Therapy for Advanced Breast Cancer**

**Presentation discussed in this issue**

Finn RS et al. **Results of a randomized Phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER-positive/HER2-negative advanced breast cancer.** San Antonio Breast Cancer Symposium 2012;**Abstract S1-6**.

**Slides from a presentation at SABCS 2012 and transcribed comments from recent interviews with Rowan T Chlebowski, MD, PhD (1/9/13) and Clifford Hudis, MD (1/11/13)**

## **Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone for First-Line Treatment of ER+/HER2-Advanced Breast Cancer (BC)**

**Finn RS et al.**

*Proc SABCS 2012;Abstract S1-6.*

Research  
To Practice®




# Background

- Preclinical studies identified an association between sensitivity to PD 0332991 and the luminal ER subtype, elevated expression of cyclin D1 and Rb and reduced p16 expression<sup>1</sup>, and also synergistic activity between tamoxifen and PD 0332991<sup>2</sup> (<sup>1</sup>*Breast Cancer Res* 2009;11(5):R77; <sup>2</sup>*Nat Rev Can* 2011;11:558).
- The current 2-part, Phase II trial was designed to evaluate PD 0332991 and letrozole (PD 991 + LET) versus letrozole alone in postmenopausal patients with ER+/HER2- breast cancer (BC).
- Interim analysis of Part 1 of this Phase II study showed a significant improvement in PFS with PD 991 + LET versus LET alone (IMPAKT Breast Cancer Conference 2012;Abstract 292).
- **Study objective:** Interim analysis of combined results of patients in both Part 1 and Part 2 of the Phase II study.

Finn RS et al. *Proc SABCS* 2012;Abstract S1-6.

Research  
To Practice®

# Phase II Study Design




Finn RS et al. *Proc SABCS* 2012;Abstract S1-6.

Research  
To Practice®



## Primary Endpoint: Progression-Free Survival



With permission from Finn RS et al. *Proc SABCS 2012*;Abstract S1-6.

Research  
To Practice®

## Best Overall Response: Patients with Measurable Disease

Response rate	PD 991 + LET	LET
Objective response (n = 64, 65)	45%	31%
Complete response	0%	0%
Partial response	45%	31%
Clinical benefit rate (n = 84, 81)	70%	44%

Finn RS et al. *Proc SABCS 2012*;Abstract S1-6.

Research  
To Practice®

## Select Treatment-Related Adverse Events (AEs)

Grade 3/4 AEs (≥10%)	PD 991 + LET (n = 83)	LET (n = 77)
Neutropenia	61.4%	1.3%
Leukopenia	16.9%	0%
Anemia	6%	1.3%
Fatigue	4.8%	1.3%
Thrombocytopenia	1.2%	0%

Finn RS et al. *Proc SABCS 2012*;Abstract S1-6.

Research  
To Practice®

## Author Conclusions

- In patients with ER+/HER2- breast cancer, the combination of PD 0332991 with letrozole shows statistically significant improvement in median PFS compared to letrozole alone.
- These results confirm the preclinical observations made with PD 0332991 in breast cancer models.
- The combination is generally well tolerated, with uncomplicated neutropenia as the most frequent adverse event.
- A randomized Phase III study is planned to start in 2013.

Finn RS et al. *Proc SABCS 2012*;Abstract S1-6.

Research  
To Practice®

## **Investigator Commentary: Phase II Study of PD 0332991 with Letrozole versus Letrozole Alone for First-Line Treatment of ER-Positive, HER2-Negative Advanced Breast Cancer**

The results of this randomized Phase II study comparing PD 0332991 with letrozole to letrozole alone demonstrated remarkable results in terms of progression-free survival (26.1 mo versus 7.5 mo). Because cyclin D is important for mitosis, inhibiting CDK 4/6 may be universally effective. Few patient-perceived side effects were reported, including Grade 3 myelosuppression but no febrile neutropenia. We will have to see whether these results are borne out in the Phase III study.

***Interview with Rowan T Chlebowski, MD, PhD, January 9, 2013***

This study showed a striking improvement in progression-free survival with PD 0332991 in combination with letrozole versus letrozole alone, and these results are exciting. We should be enthusiastic about the planned Phase III study. Currently PD 0332991 is being studied in trials as a single agent and in combination with chemotherapy.

CDK inhibitors have been studied for years, and this study was a breakout result in breast cancer. CDKs are important in cell cycle progression throughout the "malignancy spectrum," and CDK inhibitors may also be effective in other cancers.

***Interview with Clifford Hudis, MD, January 11, 2013***

Research  
To Practice®